References
Harper PS, Brook JD, Newman E. Myotonic dystrophy. London; New York: W.B. Saunders; 2001.
Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H et al (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a protein kinase family member. Cell 68(4):799–808
Philips AV, Timchenko LT, Cooper TA (1998) Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 280(5364):737–741
Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH et al (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488(7409):111–115
Wang G-S, Cooper TA (2007) Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 8(10):749–761
Nakamori M, Sobczak K, Puwanant A, Welle S, Eichinger K, Pandya S et al (2013) Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol 74(6):862–872
Index IDMC-10. Programme at a glance 17. Poster Presentation Abstracts 95 Author index 218 Attendees Contact Information 245 Notes PDF [Internet]. [cited 2018 Sep 17]. Available from: https://docplayer.net/27797227-Index-idmc-10-programme-at-a-glance-17-poster-presentation-abstracts-95-author-index-218-attendees-contact-information-245-notes-260.html
Mendell JR, Florence J (1990) Manual muscle testing. Muscle Nerve 13(Suppl):S16-20
Hébert LJ, Remec J-F, Saulnier J, Vial C, Puymirat J (2010) The use of muscle strength assessed with handheld dynamometers as a non-invasive biological marker in myotonic dystrophy type 1 patients: a multicenter study. BMC Musculoskelet Disord 11:72
Bouchard J-P, Cossette L, Bassez G, Puymirat J (2015) Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases. J Neurol 262(2):285–293
Kierkegaard M, Tollbäck A (2007) Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy. Neuromuscul Disord NMD 17(11–12):943–949
Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C et al (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257(1):91–97
Henricson E, Abresch R, Han JJ, Nicorici A, Goude Keller E, de Bie E et al (2013) The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically develo** controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr 8:5
Funding
This study was supported by Muscular Dystrophy UK and Myotonic Dystrophy Support Group (MDSG), UK and by the Polish National Science Center Grants: 2014/13/B/NZ5/03214, 2019/33/B/NZ5/02473 and 2020/39/B/NZ3/01811 (to M Wojciechowska). Muscular Dystrophy UK, MC3/1070 (to Saam Sedehizadeh).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical standards
The regional ethics committee approved the use of human participants for this study (Nottingham REC approval no. 13/EM/0173). Written informed consent was obtained from all participating patients.
Rights and permissions
About this article
Cite this article
Sedehizadeh, S., Wojciechowska, M., Ketley, A. et al. Splicing in two skeletal muscle transcripts correlates with clinical phenotype in myotonic dystrophy type 1 patients. J Neurol 269, 2784–2787 (2022). https://doi.org/10.1007/s00415-021-10917-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-021-10917-8